The Quebec Immunization Committee recommends a third dose of COVID vaccine for people who are immunocompromised. (Photo Le Reflet – Archives)
The Quebec Immunization Committee (CIQ) believes that people who are immunosuppressed or on dialysis would benefit from receiving a third dose of COVID vaccine.
“The recommendation of an additional dose of vaccine to immunocompromised people should offer them better protection against SARS-CoV-2”, informed the CIQ Monday afternoon. An opinion that he claims relevant to face the Delta variant, highly contagious. The United States, France already share this recommendation and other countries are studying this option.
The latter issued this recommendation following various analyzes. In particular, the one which suggests that people who are immunocompromised or on dialysis have an increased risk of developing complications from a COVID infection. They also have a poorer response to the COVID vaccine.
“In several studies an increase in antibodies after a third dose was observed in a majority of immunocompromised or dialysis participants who did not respond well to two doses,” can we read in the opinion. Although we do not have efficacy data from a three-dose vaccination schedule, it seems likely that people who are immunocompromised or on dialysis can improve their protection against COVID-19 with an additional dose of the vaccine. “
It is argued that the protection conferred by this additional dose may, however, be less than that of the general population after two doses.
Immunosuppression affects people:
in chemotherapy / radiotherapy for cancer
transplants of the liver, heart, lung, pancreas, intestine, intestine, intestine-pancreas and other multivisceral transplants
adults with a kidney transplant or a child who has had the same type of transplant under certain conditions
hematopoietic stem cell transplant recipients under certain conditions
who receive high doses of corticosteroids under certain conditions
who are receiving high intensity immunosuppressive therapy or daily concomitant therapy with prednisone
who have a primary immunodeficiency mainly of cellular immunity
who have HIV under certain conditions